BerGenBio
BerGenBio ASA is a Norwegian clinical-stage biopharmaceutical company focused on oncology. Based in Bergen, it develops selective inhibitors of AXL, a receptor tyrosine kinase associated with tumor growth, metastasis, and resistance to therapy. AXL signaling is also implicated in immune evasion, making AXL inhibitors a potential approach to enhance cancer therapies.
The lead candidate bemcentinib (BGB324) is an oral AXL inhibitor designed to block AXL signaling, potentially
In addition to bemcentinib, BerGenBio pursues other research programs targeting AXL and related pathways; several programs
BerGenBio is publicly traded on the Oslo Stock Exchange, with its development trajectory tied to clinical trial